0 items
Your cart is empty.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
$598.00
This product is available by prescription only
This product does not require a prescription
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
The product is delivered in powdered (lyophilized) form and must be properly reconstituted prior to research use.
The 60mg vial provides the highest available triple-agonist peptide concentration for large-scale institutional and pharmaceutical research programs. Single-vial format reduces handling frequency, simplifies storage logistics, and supports multiple concurrent protocol arms within a single procurement cycle. Lyophilized format ensures long-term structural stability for multi-year research programs, supporting consistent peptide exposure and reproducible molecular endpoint data across all extended protocol phases.
Retatrutide simultaneously co-activates three structurally related G-protein-coupled receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. Each receptor initiates distinct but overlapping downstream Gs-protein-coupled cAMP signaling cascades — GIP receptor activation is studied in relation to pancreatic beta-cell insulin secretion pathway dynamics; GLP-1 receptor activation in relation to incretin-mediated glucagon suppression pathway signaling; and glucagon receptor activation in relation to hepatic glucose production regulatory marker activity and lipid oxidation pathway endpoint expression. Simultaneous tri-receptor co-activation enables researchers to examine whether combined activation of all three receptor systems produces additive, synergistic, or pathway-competitive effects on shared downstream molecular markers relative to single- and dual-agonist reference compounds.
Retatrutide’s triple receptor activation profile distinguishes it from dual-agonist compounds such as Tirzepatide (GIP/GLP-1) and Survodutide (GLP-1/glucagon), enabling researchers to design comparative multi-arm study designs examining how the addition of a third receptor system modifies downstream signaling pathway interaction dynamics. Research quantifying the incremental molecular endpoint differences produced by tri-receptor vs. dual-receptor co-activation contributes to mechanistic understanding of receptor combination-dependent signaling biology across incretin and glucagon pathway systems.
Novera supplies Retatrutide 60mg sourced from USA GMP-certified pharmaceutical manufacturing facilities, independently verified to approximately 99% purity by COA documentation. Each vial confirms peptide sequence identity, purity grade, and batch-specific analytical characterization data — providing institutional laboratories with consistent, pharmaceutical-grade triple-agonist material suitable for regulatory-documentation-quality research records and enterprise-level program compliance requirements.
Retatrutide 60mg is suited for pharmaceutical research organizations and institutional laboratories conducting large-scale triple-agonist receptor pharmacology programs, multi-site tri-receptor signaling characterization studies, and extended multi-year preclinical research designs. Research teams examining simultaneous GIP, GLP-1, and glucagon receptor co-activation interaction dynamics, comparative tri-receptor vs. dual-agonist signaling endpoint differences, or comprehensive pharmacokinetic and pharmacodynamic characterization across multiple receptor systems benefit from this maximum-concentration format. The 60mg vial supports multi-arm institutional study designs requiring high peptide availability across extended 104–156 week observation programs, reducing procurement complexity and supporting consistent material availability at enterprise research scale. Novera supplies Retatrutide 60mg sourced from USA GMP-certified manufacturing facilities, with each vial COA-verified for purity and sequence identity to approximately 99%.
Retatrutide supports in-vitro investigation of simultaneous GIP, GLP-1, and glucagon receptor binding kinetics, receptor occupancy dynamics, and downstream cAMP second messenger pathway activity across multiple receptor systems in pancreatic, hepatic, and hypothalamic cell line experimental models. Researchers characterizing tri-receptor selectivity profiles, binding affinity parameter comparison across all three receptor systems, and competitive binding assay endpoint dynamics use Retatrutide as a primary reference agonist for next-generation incretin receptor pharmacology study designs.
Laboratories studying tri-receptor signal transduction use Retatrutide to quantify downstream molecular marker activity simultaneously across GIP-mediated insulin secretion pathway endpoints, GLP-1-mediated glucagon suppression signaling markers, and glucagon receptor-mediated hepatic lipid oxidation pathway expression in controlled preclinical metabolic model systems. Multi-arm protocols comparing triple-agonist and dual-agonist downstream signaling endpoint profiles support mechanistic characterization of receptor combination-dependent molecular interaction dynamics across shared and distinct pathway markers.
Retatrutide supports comprehensive pharmacokinetic profiling — including plasma stability characterization, receptor exposure duration parameters, and tissue distribution marker dynamics — alongside pharmacodynamic endpoint quantification across all three receptor systems simultaneously. Institutional research programs conducting complete PK/PD characterization for pharmaceutical development applications use the 60mg concentration to support multi-arm, multi-timepoint study designs with sufficient material availability across extended 104–156 week observation periods.
The 60mg format enables large-scale multi-site research program designs where consistent peptide material availability across geographically distributed laboratory facilities is required. Pharmaceutical research organizations conducting multi-arm triple-agonist mechanism characterization programs, dose-escalation response profiling, and comparative receptor pharmacology studies across multiple concurrent institutional sites benefit from the operational efficiency this maximum-concentration format provides.
Reconstitute lyophilized Retatrutide 60mg with USP-grade sterile bacteriostatic water using GMP-compliant sterile technique in certified laboratory facilities. Reconstitution volume should be determined based on the target experimental working concentration and protocol arm dosing requirements specified by the study design. Document all reconstitution steps in accordance with institutional analytical validation standards and regulatory-quality research record-keeping requirements. Use calibrated equipment throughout all preparation steps.
Store lyophilized peptide at 2–8°C under validated environmental controls in certified laboratory storage conditions, protected from light and moisture, prior to reconstitution. Following reconstitution, maintain pharmaceutical-grade refrigeration at 2–8°C to preserve triple-agonist peptide integrity. This product does not require cold-chain shipping, but standard pharmaceutical receiving and storage procedures should be followed upon receipt. Each vial supplied by Novera includes COA documentation, analytical characterization data, and handling guidance.
Institutional research programs using Retatrutide 60mg typically support 104–156 week multi-year protocols for comprehensive tri-receptor pharmacology characterization and longitudinal signaling pathway marker progression observation. Studies systematically monitor GIP, GLP-1, and glucagon receptor pathway panel activity markers, pharmacokinetic parameter endpoints, and downstream metabolic signaling marker expression at defined intervals throughout the extended observation period. The 60mg format supports efficient multi-year program execution with consistent material availability across all concurrent protocol arms and institutional research sites.
Novera Research delivers high-quality research peptides developed under strict manufacturing and quality-control standards. Each product is carefully synthesized, tested, and handled to ensure consistency, reliability, and transparency for advanced research applications.
High-purity, research-grade peptide synthesis
Analytical testing to verify quality and composition
Consistent batch-to-batch performance
Batch identification on every vial for traceability
Stored and shipped under controlled conditions
Research-grade decapeptide signaling molecule formulated for experimental peptide pathway research in controlled laboratory environments.
A synthetic GHRH analog studied for receptor binding kinetics, molecular interaction modeling, and pulsatile signaling pathway investigation in preclinical settings.
Research-grade synthetic dual-peptide formulation combining amylin analog and GLP-1 receptor agonist for dual-mechanism pathway studies and combination peptide research in controlled laboratory environments.
Research-grade synthetic dual-agonist peptide formulated in higher-quantity 15mg format for extended dual-receptor pathway studies and institutional peptide research in controlled laboratory environments.
Research-grade synthetic peptide fragment formulated for advanced laboratory peptide research and experimental scientific protocols. Disclosure: This product is intended for research purposes only and is not intended for human consumption...
